Publications by authors named "Stephan Ruetz"

Claim this Profile
D
Discovery, X-ray structure and CPP-conjugation enabled uptake of p53/MDM2 macrocyclic peptide inhibitors.
Anselm F L Schneider, Joerg Kallen, Johannes Ottl, Patrick C Reid, Sebastien Ripoche, Stephan Ruetz

RSC Chem Biol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.
Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, Jeanette Fuchs, Emilie A Chapeau, Stephan Ruetz

Cancer Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.
Andrea Vaupel, Philipp Holzer, Stephane Ferretti, Vito Guagnano, Joerg Kallen, Stephan Ruetz

Bioorg Med Chem Lett· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A critical assessment of the synthesis and biological activity of p53/human double minute 2-stapled peptide inhibitors.
Rike Wallbrecher, Patrick Chène, Stephan Ruetz, Therese Stachyra, Thomas Vorherr

Br J Pharmacol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, Hans Bitter, Moriko Ito, Stephan Ruetz

Elife· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument.
Pascal Furet, Keiichi Masuya, Joerg Kallen, Thérèse Stachyra-Valat, Stephan Ruetz

Bioorg Med Chem Lett· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.
François Gessier, Joerg Kallen, Edgar Jacoby, Patrick Chène, Thérèse Stachyra-Valat, Stephan Ruetz

Bioorg Med Chem Lett· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
Philipp Holzer, Keiichi Masuya, Pascal Furet, Joerg Kallen, Therese Valat-Stachyra, Stephan Ruetz

J Med Chem· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, Hans Bitter, Moriko Ito, Stephan Ruetz

Elife· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double blinded, placebo-controlled pilot study to examine reduction of CD34 /CD117 /CD133 lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma.
Daisuke Ito, Michael Childress, Nicola Mason, Amber Winter, Timothy O'Brien, Stephan Ruetz

F1000Res· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.
Fabienne Baffert, Catherine H Régnier, Alain De Pover, Carole Pissot-Soldermann, Gisele A Tavares, Stephan Ruetz

Mol Cancer Ther· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800.
Andrew J Massey, Joseph Schoepfer, Paul A Brough, Josef Brueggen, Patrick Chène, Stephan Ruetz

Mol Cancer Ther· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantified tumor t1 is a generic early-response imaging biomarker for chemotherapy reflecting cell viability.
Paul M J McSheehy, Claudia Weidensteiner, Catherine Cannet, Stephane Ferretti, Didier Laurent, Stephan Ruetz

Clin Cancer Res· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cis-stilbene derived furopyranones show potent antiproliferative activity by inducing G2/M arrest.
Cyril A Fuhrer, Eric Grüter, Stephan Ruetz, Robert Häner

ChemMedChem· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.
Iwan Beuvink, Anne Boulay, Stefano Fumagalli, Frederic Zilbermann, Stephan Ruetz

Cell· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The human ubiquitin-conjugating enzyme Cdc34 controls cellular proliferation through regulation of p27Kip1 protein levels.
Nicole Butz, Stephan Ruetz, Francois Natt, Jonathan Hall, Jan Weiler

Exp Cell Res· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.
Carlos García-Echeverría, Mark A Pearson, Andreas Marti, Thomas Meyer, Juergen Mestan, Stephan Ruetz

Cancer Cell· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Doriano Fabbro, Stephan Ruetz, Elisabeth Buchdunger, Sandra W Cowan-Jacob, Gabriele Fendrich

Pharmacol Ther· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
beta-Homolysine oligomers: a new class of Trojan carriers.
C García-Echeverría, Stephan Ruetz

Bioorg Med Chem Lett· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors.
Stephan Ruetz, Doriano Fabbro, Juerg Zimmermann, Thomas Meyer, Nathanael Gray

Curr Med Chem Anticancer Agents· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.
Jeanette Wood, Karine Bonjean, Stephan Ruetz, Akeila Bellahcène, Laetitia Devy

J Pharmacol Exp Ther· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis